Management of Leukocytosis with Neutrophilia
Assessment and Antibiotic Management
- Empirical broad-spectrum antimicrobial therapy is mandatory for patients with neutrophilia who are febrile and profoundly neutropenic, as recommended by the European Hematology Association 1
- Bacterial infections are the most common cause of leukocytosis with neutrophilia, and evaluation for potential causes should include consideration of bacterial infections, according to the Infectious Diseases Society of America 1, 2
- Initiate empirical broad-spectrum antimicrobial therapy immediately for febrile patients with neutropenia, as recommended by the European Hematology Association and the Infectious Diseases Society of America 1, 2
- First-line options for empirical broad-spectrum antimicrobial therapy include levofloxacin 500mg orally daily and ciprofloxacin 500mg orally twice daily, as recommended by the Infectious Diseases Society of America 2
- For more severe cases, consider ceftazidime, meropenem, or other broad-spectrum IV antibiotics, as recommended by the European Society for Medical Oncology 3
Monitoring and Supportive Care
- Daily assessment of fever trends, bone marrow and renal function is indicated until the patient is afebrile and ANC ≥ 0.5 × 10⁹/l, as recommended by the European Society for Medical Oncology 4
- Consider granulocyte colony-stimulating factor (G-CSF; filgrastim) to reduce the incidence of myelosuppression and infections in patients with severe neutropenia, as recommended by the Society for Immunotherapy of Cancer 5
- Maintain hemoglobin levels ≥7.0 g/dL through packed red blood cell transfusions as needed, as recommended by the Society for Immunotherapy of Cancer 5
Special Considerations
- If active infection is present, attempt to control infection before instituting intensive therapy regimens, as recommended by the American Society of Hematology 6
- For patients with pneumonia, extend antibiotic coverage to treat atypical organisms by adding a macrolide antibiotic to a β-lactam antibiotic, as recommended by the European Society for Medical Oncology 3
Management of Leukocytosis with Neutrophilia
Initial Assessment and Risk Stratification
- A degree of leukocytosis (WBC 14.6 × 10⁹/L) with neutrophilia (73%) is commonly reactive rather than malignant, particularly in the context of acute infection or inflammatory processes, according to the Anaesthesia guideline society 7
- Leucocytosis and neutrophilia occur in 45% and 60% of patients with trauma as a reactive response, not necessarily infection, as stated by the Anaesthesia guideline society 7
Empirical Antibiotic Management
- For patients with suspected infection, intravenous therapy with Ceftazidime, meropenem, or piperacillin-tazobactam may be considered, as recommended by the Annals of Oncology guideline society 8
Diagnostic Workup
- Basic metabolic panel and renal function tests are essential immediate tests, according to the Annals of Oncology guideline society 8
Monitoring and Follow-up
- Daily assessment of fever trends, vital signs, and clinical response to antibiotics is required until resolution, as stated by the Annals of Oncology guideline society 8
- If patient becomes afebrile within 48 hours and clinically stable, continue antibiotics for appropriate duration based on infection source, as recommended by the Annals of Oncology guideline society 8
- If fever persists beyond 48 hours despite antibiotics, reassess for alternative infection sources and consider broadening antibiotic coverage, according to the Annals of Oncology guideline society 8
Special Considerations
- Non-infectious causes of leukocytosis, such as medications (corticosteroids, lithium, G-CSF), smoking, chronic inflammatory conditions, and recent surgery or trauma, should be considered if infection is excluded, as stated by the Annals of Oncology guideline society 8